Research programme: cancer therapeutics - TP Therapeutics

Drug Profile

Research programme: cancer therapeutics - TP Therapeutics

Alternative Names: TPX 0005

Latest Information Update: 26 May 2016

Price : $50

At a glance

  • Originator TP Therapeutics
  • Class Macrocyclic compounds
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Proto-oncogene protein pp60(c-src) inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 26 May 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) ,
  • 23 Mar 2016 Preclinical trials in Solid tumours in USA (unspecified route)
  • 23 Mar 2016 TP Therapeutics plans to file an IND application with the US FDA in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top